![]()
|
|
||||||||
(Received for publication, February 28, 1996, and in revised form, April 26, 1996)
From the Departments of Hepatocytes were cultured in the presence of
recombinant tumor necrosis factor (TNF) TNF1 Evaluation of the regenerating liver after partial hepatectomy (PH)
suggests that TNF An adult rat hepatocyte line (RALA255-10G) was
obtained from Dr. Janice Yang Chou in NIH (Human Genetics Branch,
National Institute of Child Health and Human Development, Bethesda, MD)
(17). Recombinated TNF The SV40 tsA255 virus-transformed rat adult
liver cell line RALA255-10G (17) was initially grown in Dulbecco's
modified Eagle's medium (Life Technologies, Inc.) supplemented with
4% fetal bovine serum for 3-5 days at 33 °C. When cells reached
about 70% confluence (time 0), cultures were treated with human
recombinant TNF Total RNA was extracted from
cultured cells by the method of Chomczynski and Sacchi (21). 20 µg/lane of RNA samples was fractionated on denaturing agarose gels
and transferred to GeneScreen membranes (NEN Research Products, Boston,
MA). Membranes were stained with 0.04% methylene blue to confirm the
lane-lane equivalency of RNA loading/transfer and then hybridized with
cDNA probes for C/EBP Parallel
plates of similarly confluent cultures were used to isolated nuclear
and whole cell protein. Nuclear protein was isolated by NUN buffer as
described (22) with some modification. Briefly, cells were lysed in 10 mM Hepes, pH 7.5, 0.5 mM spermidine, 0.15 mM spermine, 5 mM EDTA, 1 mM
dithiothreitol, 0.35 mM sucrose, and 0.5% Nonidet P-40.
Nuclei were pelletted by centrifugation at 12000 × g
and resuspended in NUN buffer containing 25 mM Hepes, pH
7.5, 300 mM NaCl, 1 M urea, 1% Nonidet P-40,
and 1 mM dithiothreitol. Chromatin was removed by
centrifugation, and the nuclear protein extract was aliquoted and
stored at Treatment-related variations in C/EBP proteins were analyzed by
Western blot, as described previously (7). In brief, proteins were
separated on 12% SDS-polyacrylamide gel electrophoresis and
transferred onto Immobilon-P membranes (Millipore Co. Bedford, MA). The
blots were probed with affinity-purified polyclonal anti-C/EBP Subcellular localization of
C/EBPs was examined by fluorescent immunocytochemical staining of RALA
cells according to Tse et al. (23). Cells were cultured on
glass slides and fixed in 2% paraformaldehyde, 0.1 M
lysine, 0.01 M sodium periodate, and 0.05 M
phosphate buffer. After quenching with 0.25% NH4Cl and
permeabilizing with 0.06% digitonin, slides were blocked with 0.2%
gelatin, immunostained with primary antibodies to C/EBP Gel mobility shift assays were
performed as described by Garner and Revzin (24) and Fried and Crothers
(25). Each 20-µl reaction mixture contained 8-10 µg of nuclear
protein plus a To determine if TNF
The finding that TNF Although it is apparent that several pro-inflammatory cytokines can
increase the activity of C/EBP The present experiments were designed to minimize these obstacles. The
anti-C/EBP TNF TNF activation of its receptors initiates signals that regulate gene
expression at multiple levels. Post-transcriptional mechanisms appear
to play particularly important roles in TNF
Volume 271, Number 30,
Issue of July 26, 1996
pp. 17974-17978
©1996 by The American Society for Biochemistry and Molecular Biology, Inc.
Promotes Nuclear Localization of
Cytokine-inducible CCAAT/Enhancer Binding Protein Isoforms in
Hepatocytes*
,
,
,

Medicine,
§ Biological Chemistry, and ¶ Pediatrics, Johns Hopkins
University, Baltimore, Maryland 21205
or mutated TNF
peptides
that specifically activate either p55 or p75 TNF receptors to determine
if TNF
can activate cytokine-inducible CCAAT/enhancer binding
protein (C/EBP) isoforms by post-transcriptional mechanisms that are
initiated by TNF receptors. Within 5-10 min after treatment with any
of these agents, nuclear concentrations of C/EBP
and C/EBP
double and remain 2-4-fold greater than control cultures for 30 min
(p < 0.01). Consistent with these results, gel mobility
shift assays demonstrate 3-fold increased nuclear C/EBP
- and C/EBP
-DNA binding activity in TNF
-treated cells, and
immunocytochemistry confirms rapid redistribution of these C/EBP
isoforms into the nucleus. In contrast, mRNA and whole cell protein
concentrations of C/EBP
and
are not altered by TNF
exposure, and nuclear concentrations of another C/EBP isoform, C/EBP
, are decreased by 80%. This novel evidence that TNF
initiates
post-transcriptional activation of cytokine-inducible C/EBP isoforms
identifies a mechanism that enables hepatocytes to respond immediately
to inflammatory stress.
is a pleotropic cytokine.
Diverse phenotypic responses to TNF
reflect, at least in part, its
ability to modulate the activity of both ubiquitous and tissue-specific
transcription factors. For example, in many cells, TNF
initiates
mitogen-activated protein kinase cascades, which modulate the
transcriptional and/or DNA binding activity of AP-1 components. In
macrophages, transcription of c-fos is induced by TNF
-initiated signals that activate microtubule-activated protein early
response kinase, microtubule-activated protein early response kinase
kinase, and early response kinase, leading to phosphorylation of ELK-1,
which, in turn, increases the transcription of c-fos (1). In
fibroblasts, TNF
induces Jun nuclear kinase, which phosphorylates
and transcriptionally activates c-Jun, promoting increased expression
of this transcription factor (2). TNF
can also induce NF-
activity by triggering events that favor redistribution of this
transcription factor from the cytosol to the nucleus (3, 4, 5). Taken
together, these data demonstrate that TNF
employs several
post-transcriptional mechanisms to activate an array of ubiquitous
transcription factors, which, in turn, influence the expression of
diverse target genes.
may also operate post-transcriptionally to
activate members of the CCAAT/enhancer binding protein (C/EBP) family
of transcription factors. Nuclear concentrations of C/EBP
and C/EBP
proteins increase early during the prereplicative period after PH
(6, 7, 8, 9, 10). These increases are inhibited in animals pretreated with
neutralizing anti-TNF antibodies, although there is no difference in
post-PH induction of their respective mRNAs (7). Because the C/EBPs
regulate tissue-specific gene expression in hepatocytes, TNF-mediated
alterations in C/EBP activity are likely to modulate liver-specific
functions during liver regeneration. Indeed, during systemic
inflammation, another situation that increases TNF
, the profile of
hepatocyte gene expression is altered radically (11). In that setting,
TNF
is thought to regulate hepatocyte gene expression indirectly by
inducing other cytokines (e.g., interleukins 1 and 6) that
can interact directly with hepatocytes to activate C/EBP
and C/EBP
(11, 12, 13, 14). Because IL-1 and IL-6 are also induced after PH (15, 16),
it is unclear if TNF
or other cytokines are responsible for the
observed variations in C/EBP expression that occur in the regenerating
liver. The purpose of this study was to evaluate the effect of human
recombinant TNF
and synthetic TNF peptides that specifically
activate either class 1 or class 2 TNF receptors on nuclear
concentrations of C/EBP
and C/EBP
in cultured hepatocytes and
to determine if TNF-induced changes in the nuclear concentrations of
these proteins require altered expression of their mRNAs. Our
results indicate that activation of both classes of TNF receptors
rapidly induce a transient increase in the nuclear concentrations of
these C/EBP family members without altering the expression of their
mRNAs or increasing total cellular concentrations of these C/EBP
isoforms. Immunocytochemistry suggests that TNF-initiated changes in
the subcellular distribution of C/EBP
and C/EBP
are involved in
post-transcriptional regulation of C/EBP activity.
Materials
was purchased from Genetech (San Francisco,
CA). Mutated TNF polypeptides that bind specifically to either the p55
(R32W-S86T) or p75 (D143N-A145R) TNF receptors (18) were gifts from Dr.
Subroto Chatterjee (Dept. of Pediatrics, Johns Hopkins University,
Baltimore, MD). cDNAs and antibodies to C/EB P
, C/EBP
, and
C/EBP
were generously provided by Dr. M. Daniel Lane (Department of
Biological Chemistry, Johns Hopkins University, Baltimore, MD) (19).
Antibodies were prepared by immunizing rabbits with peptides
corresponding to an internal amino acid sequence of C/EBP
(present
in both p42C/EBP
and p30C/EBP
) or to amino
acids 278-295 (LRNLFKQLPEPLLASAGH) of C/EBP
or 115-130
(ARGPLKREPDWGDGDA) of C/EBP
. As previously reported,
affinity-purified antiserum used for Western blots or supershifting was
specific for each C/EBP isoform, and interactions with other C/EBP
isoforms were not observed (19, 20). All the other chemicals were from
Sigma or J. T. Baker Inc. (Phillipsburg, NJ).
or TNF mutant polypeptides for variable periods of
time, ranging from 5 min to 24 h.
and C/EBP
as described previously
(7). After washing under stringent conditions, membranes were exposed
to Kodak XAR film with intensifying screens. Autoradiograms from three
to four unique experiments were analyzed by scanning laser densitometry
(Molecular Dynamics, Sunnyvale, CA).
70 °C. To isolate the whole cell protein, cells were
washed with cold phosphate-buffered saline and lysed on ice in RIPA
buffer (phosphate-buffered saline, 1% Nonidet P-40, 0.5% sodium
deoxycholate, 0.1% SDS, and 10 mM phenylmethylsulfonyl
fluoride) followed by centrifugation. The soluble protein portion was
stored at
70 °C.
,
anti-C/EBP
, or anti-C/EBP
antibodies, and proteins were
visualized by the Enhanced Chemiluminescence detection system (Amersham
Corp.). Blots obtained from three to four unique experiments were
evaluated by scanning laser densitometry (Molecular Dynamics,
Sunnyvale, CA).
or C/EBP
, and visualized by staining with the fluorescein
isothiocyanate-conjugated secondary antibody to rabbit IgG (Kirkgaard & Perry Lab. Inc., Gaithersburg, MD). Slides were examined under Zeiss
Axioplan fluorescence microscope by two independent observers, and the
number of cells with predominately nuclear or predominately cytoplasmic
staining were quantitated in 10 high power (400×) fields/slide.
Interobserver variation was <2%.
-32P-labeled 25-base pair oligonucleotide
probe containing the C/EBP binding site in the c-fos
promoter (26) in binding buffer (10 mM Hepes, pH 7.5, 0.5 mM spermidine, 0.15 mM spermine, 5 mM EDTA, 10 mM dithiothreitol, 0.35 mM sucrose). The reaction mixture was incubated at room
temperature for 15 min and loaded directly onto a 6.5% polyacrylamide
(49:0.6 acrylamide/bisacrylamide) gel in a buffer of 25 mM
Tris borate (pH 8.0), 0.25 mM EDTA. In some experiments,
antisera specific for unique C/EBP isoforms or preimmune sera were
added to reaction mixtures to determine the composition of
protein-probe complexes. For these ``supershift'' assays, extracts
were incubated with 1 µl of preimmune sera or an equal volume of
anti-C/EBP
, anti-C/EBP
, and/or anti-C/EBP
antisera at
4 °C for 30 min prior to addition of
-32P-labeled
probe. In all experiments, proteins were separated by electrophoresis
at 200 V for 2 h at room temperature. Gels were dried and exposed
to Kodak XAR film with intensifying screens. Assays were repeated with
nuclear extracts obtained from three unique experiments and evaluated
by phosphoimage analysis to ensure reproducibility of results.
acts directly on hepatocytes to alter
nuclear concentrations of C/EBP
and/or C/EBP
, human recombinant
TNF
was added to the SV40 virus conditionally transformed adult rat
hepatocyte line (RALA255) during culture at the permissive temperature
(33 °C). As shown in Fig. 1, nuclear concentrations
of C/EBP
and C/EBP
double within 5 min of TNF treatment and
remain 2-4-fold greater than untreated cultures for 30 min. Increased
nuclear concentrations of the C/EBPs are not likely to be mediated by
increased synthesis of these proteins because mRNA and whole cell
protein concentrations of C/EBP
(Fig. 2) and C/EBP
(data not shown) remain relatively constant during this time.
Immunocytochemistry indicates that under these conditions, TNF causes a
rapid redistribution of C/EBP
(Fig. 3) and C/EBP
(Fig. 4) into the nucleus. To determine if these effects
of human recombinant TNF
, which predominately activates class 1 TNF
receptors, can also result from TNF receptor 2-initiated signals,
experiments were repeated with synthetic peptide ligands that have been
shown to selectively activate either class 1 (p55) or class 2 (p75) TNF
receptors (18). As shown in Fig. 5, nuclear
concentrations of C/EBP
increase within 5 min and remain elevated
for 30 min after treatment with either ligand. Increases in nuclear
C/EBP
are also short-lived but appear to occur sooner after the
addition of the p75 agonist than after addition of the p55 agonist.
Thus, both ligands cause a rapid, albeit transient, increase in the
nuclear concentrations of C/EBP
and C/EBP
. In contrast, nuclear
concentrations of a closely related transcription factor, C/EBP
,
transiently decrease after treatment with either agent (Fig. 5). TNF
-dependent increases in the nuclear concentrations of
C/EBP
and C/EBP
are accompanied by increased binding activity
of these C/EBP isoforms. As shown in Fig. 6, complex
formation between nuclear extracts and the oligonucleotide probe is
increased 3-fold in cells treated with either the p55 or p75 mutein for
10 min. Supershift experiments confirm that this is predominately due
to increased C/EBP
and C/EBP
binding activity (Fig. 6).
Fig. 1.
TNF
induces nuclear accumulation of C/EBP
and C/EBP
proteins. 33 °C RALA cells were treated with
human recombinant TNF
(60 ng/ml). Nuclear protein was purified from
cells before (time 0) or at various times (5, 10, 30, or 180 min) after
the addition of TNF
. Treatment-related variations in the expression
of C/EBP
and C/EBP
proteins were analyzed by Western blot (40 µg of nuclear protein/lane) (A) and quantitated by laser
densitometry scanning (B). The relative protein levels are
given as the means ± S.E. of three separate blots for either
C/EBP
or C/EBP
. *, p < 0.05.
Fig. 2.
Effect of TNF
on the expression of C/EBP
mRNA and total cellular C/EBP
protein. Parallel RALA
cell cultures were maintained at 33 °C and treated with the same
concentration of human recombinant TNF
(60 ng/ml) for 0, 10, 30, or
180 min. Total RNA was isolated from one group and treatment-related
variations in C/EBP
mRNA levels were evaluated by Northern blot
analysis as described under ``Experimental Procedures.'' Cell lysates
were prepared from the other cultures at identical time points, and
variations in whole cell C/EBP
protein expression were analyzed by
Western blot (100 µg of total cellular protein/lane) as detailed
under ``Experimental Procedures.''
Fig. 3.
Subcellular localization of C/EBP
protein
before and after TNF
treatment. RALA255-10G cells were
cultured at 33 °C; human recombinant TNF
(60 ng/ml) was added to
the plates for 30 min, and then the plates were washed extensively and
processed for immunocytochemistry (see ``Experimental Procedures'')
to detect treatment-related differences in the compartmentalization of
C/EBP
protein. In all experiments, parallel cultures treated with
preimmune sera or primary anti-C/EBP
antisera that had been
preincubated with in vitro translated C/EBP
protein
demonstrated no fluorescence after treatment with the secondary
fluorescein isothiocyanate-conjugated antibody (data not shown).
A, representative photomicrographs of anti-C/EBP
stained
cells before and after TNF
treatment. B, graphical
summary of results obtained in four separate experiments. Over 100 positively stained cells were counted in each experiment and ranked for
either predominately nuclear or predominately cytoplasmic staining by
two independent observers who were unaware whether or not the slides
were obtained before or after TNF treatment. Data demonstrate the
means ± S.E. percentage of cells with either nuclear or
cytoplasmic staining for each condition.
Fig. 4.
Subcellular localization of C/EBP
protein
before and after TNF
treatment. RALA255-10G cells were
treated as described in the legend to Fig. 3, and cultures were
processed to detect treatment related differences in the
compartmentalization of C/EBP
protein. A, representative
photomicrographs of anti-C/EBP
stained cells before and after TNF
treatment. B, graphical summary of results obtained in
three unique experiments. The data were obtained as described in the
legend to Fig. 3. The results are expressed as the mean
percentages ± S.E.
Fig. 5.
Effect of mutant TNF ligands on nuclear
concentrations of different C/EBP isoforms. 33 °C RALA cells
were treated with mutant peptides that specifically bind to either TNF
class-1 (p55) or TNF class-1 (p75) receptors. Each ligand was used at a
final concentration of 60 ng/ml. Nuclear protein was purified from
cells before (time 0) or at various time points (5, 10, or 30 min and 3 or 24 h) after addition the of each ligand. Treatment-related
variations in C/EBP
(top panel), C/EBP
(middle
panel), and C/EBP
(bottom panel) expression were
analyzed by Western blot (40 µg of nuclear protein/lane; see
``Experimental Procedures''). The results shown were obtained by
reprobing a single blot for each isoform. Densitometric analysis of
four unique blots confirms the reproducibility of these results.
Fig. 6.
DNA binding activities of C/EBPs in RALA
cells. A, oligonucleotides containing the C/EBP binding site
in c-fos promoter were incubated with nuclear extracts from
RALA cells cultured at 33 °C without (lanes 1-4) or with
p55 TNF muteins (lanes 5-8) or p75 TNF muteins (lanes
9-12) as described under ``Experimental Procedures.'' The
DNA-protein complexes were separated from free probe by polyacrymide
gel electrophoresis. In some reactions (lanes 2-4,
6-8, and 10-12), specific antibodies against
C/EBPs were added to the binding reaction to distinguish the binding
specificity. Lanes 2, 6, and 10 include antisera to C/EBP
; lanes 3, 7, and
11 include antisera to C/EBP
; and lanes 4,
8, and 12 include antisera to C/EBP
.
Supershifting of protein-probe complexes is apparent only in lanes that
include antisera to C/EBP
or C/EBP
. B, control
experiments confirm specificity of binding reactions with this
oligonucleotide. Comparison of lanes 1 (no protein),
2 (10 µg of protein), and 4 (2 µg of protein)
demonstrates that binding activity is dependent on protein
concentration. The addition of antisera to C/EBP
, C/EBP
, and
C/EBP
(lane 3) or 20-fold molar excess unlabeled C/EBP
oligonucleotide (lane 5) significantly reduces binding
activity; 20-fold molar excess unlabeled AP-1 oligonucleotide does not
(lane 6).
receptor activation directly stimulates
nuclear accumulation of C/EBP
and C/EBP
in hepatocytes is
novel. Published work in animal models suggests that during acute
inflammatory responses, TNF
modulates the hepatocyte phenotype
indirectly, by inducing other cytokines such as IL-1 and IL-6 (11).
Although recombinant TNF
can down-regulate C/EBP
expression in
several cell lines (27), an indirect role for TNF
in C/EBP
and
C/EBP
induction has been presumed because, in vitro,
recombinant IL-1 or IL-6 can reproduce most of changes in
C/EBP-regulated gene expression that occur in vivo during an
acute inflammatory response. In particular, IL-1 and IL-6 have been
shown to increase the respective DNA binding activities of C/EBP
and C/EBP
, important transcriptional regulators of hepatic acute
phase response genes (11, 12, 13, 14). The present results demonstrate that at
least in this conditionally transformed adult hepatocyte line, TNF
interacts directly with its receptors to rapidly increase nuclear
concentrations of these C/EBP isoforms. Indeed, this in
vitro response closely mimics the kinetics of C/EBP
and
induction, which occurs during liver regeneration after PH in intact
rats (6, 7, 8, 9, 10). This observation, coupled with the fact that PH induction
of these C/EBP isoforms is inhibited by pretreatment with neutralizing
anti-TNF antibodies (7), suggests that TNF
may also directly
mediate C/EBP
and C/EBP
induction in vivo.
and C/EBP
in hepatocytes, the
mechanisms involved have not been identified. To our knowledge, altered
compartmentalization of cytokine-inducible C/EBP isoforms have not been
reported after treatment with TNF
or TNF-inducible cytokines.
Perhaps this is because technical problems are likely to confound
efforts to identify variations in the subcellular localization of these
C/EBPs in hepatocytes. Commercially available anti-C/EBP
and
anti-C/EBP
antibodies recognize several cross-reacting antigens on
immunoblots of liver extracts (28), and hence, immunocytochemical
variations in antigen expression may be nonspecific. Furthermore,
hepatocyte isolation and culture conditions often induce C/EBP
and
C/EBP
(9, 10), making it difficult to detect further
cytokine-mediated induction of these isoforms.
and anti-C/EBP
antibodies employed were raised
against specific internal domains of each C/EBP peptide (19, 20) and
affinity-purified, and antibody specificity was validated by immunoblot
analysis before proceeding to immunocytochemistry. All
immunocytochemical data were also confirmed by immunoblot and gel
mobility shift analyses of nuclear extracts prepared from parallel
cultures. Studies were done in RALA255 cells, a conditionally
transformed adult hepatocyte line that was selected because when
cultured at the permissive temperature, this cell line expresses
trivial levels of C/EBP
and C/EBP
proteins in the nucleus (29,
30). In this regard, RALA255 cells cultured at 33 °C more closely
approximate mature hepatocytes in the healthy liver than do hepatocytes
in primary culture, because hepatocytes in the healthy adult liver
constitutively express relatively little C/EBP
and C/EBP
(6, 7, 8, 9). Low ``background'' nuclear expression of these C/EBP isoforms
in RALA255 hepatocytes facilitates identification of TNF
-mediated
increases in nuclear C/EBP
and C/EBP
concentrations.
is recognized by a binary system of receptors with apparent
molecular masses of 55 (p55) and 75 kDa (p75), which belong to the
TNF/nerve growth factor receptor family. Binding of TNF
to either
receptor provokes receptor oligomerization and initiates signal
transduction. Most cell lines and primary tissues coexpress both
receptor types, although distinct mechanisms control expression of p55
and p75. Typically, p55 is constitutively expressed at relatively low
levels, whereas p75 expression is induced by external stimuli (31, 32).
Different cellular proteins associate with the two receptors,
suggesting that they may independently regulate separate cellular
responses (33, 34). For example, specific activation of p55 typically
induces cytotoxicity (35, 36, 37), whereas stimulation of p75 often induces
proliferation (37, 38, 39), although cooperative interactions between the
two classes of receptors have also been documented (40, 41). Recent
evidence suggests that the two receptors may also differ in their
sensitivity to different forms of TNF
. In several cell lines, p55
is activated preferentially by soluble TNF
, whereas
membrane-associated TNF
is a better activator of p75 (14). The
present results indicate that in rat hepatocytes, both TNF receptors
can initiate signals that result in nuclear localization of C/EBP
and C/EBP
. Indeed, given the relatively low affinity of rodent p75
receptors for the p75 mutants (18), similarities in the responses
evoked by the two TNF mutants suggest that p75 may play a major role in
transducing this TNF
-initiated signal in vivo,
particularly after PH when hepatic TNF
expression is relatively
modest (42).
regulation of
transcription factors. For example, TNF
induces Jun nuclear kinase,
which phosphorylates c-Jun, increasing the transcriptional activity of
AP-1 (2). TNF
also leads to hyperphosphorylation of I
B
, which
permits NF-
B to move into the nucleus and activate the transcription
of
B-regulated genes (3, 4, 5). Post-transcriptional events have been
incriminated in cytokine-dependent induction of C/EBP
and
because treatment with agents (e.g., bacterial
lipopolysaccharide) that increase TNF
and TNF-inducible cytokines
stimulates dramatic increases in the DNA binding activities of C/EBP
and C/EBP
but induces relatively small increases in the
transcription of these C/EBPs (12). C/EBP
can be a target for
post-transcriptional regulation. Both protein kinase A (43) and calcium
calmodulin-dependent kinase (44) have been shown to
phosphorylate C/EBP
. Phosphorylation modulates the DNA binding and
transcriptional activity of C/EBP
, but it is unknown if changes in
phosphorylation influence subcellular compartmentalization of this
protein. However, in one report, treatments that increased cAMP in
PC-12 cells led to a redistribution of C/EBP
from the cytosol to
the nucleus (26). The present results demonstrate that TNF
induces
nuclear localization of C/EBP
. This is unlikely to be mediated by
cAMP-dependent mechanisms because TNF
inhibits
activation of adenylyl cyclase and reduces intracellular cAMP
concentrations (45). Further investigation of the mechanisms
responsible for TNF
-initiated redistribution of cytokine-inducible
C/EBP isoforms will be required to clarify the molecular basis for this
response. The process has important physiological implications because
it permits TNF
to affect rapid changes in hepatocyte gene
transcription, enabling these cells to respond immediately to acute
inflammatory stress.
*
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
``advertisement'' in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: 912 Ross Bldg.,
Johns Hopkins University, 720 Rutland St., Baltimore, MD 21205. Tel.:
410-955-7316; Fax: 410-955-9677.
1
The abbreviations used are: TNF, tumor necrosis
factor; PH, partial hepatectomy; C/EBP, CCAAT/enhancer binding protein;
IL, interleukin.
©1996 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
B. Csoka, Z. H. Nemeth, L. Virag, P. Gergely, S. J. Leibovich, P. Pacher, C.-X. Sun, M. R. Blackburn, E. S. Vizi, E. A. Deitch, et al. A2A adenosine receptors and C/EBP{beta} are crucially required for IL-10 production by macrophages exposed to Escherichia coli Blood, October 1, 2007; 110(7): 2685 - 2695. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Mameli, S. L. Deshmane, M. Ghafouri, J. Cui, K. Simbiri, K. Khalili, R. Mukerjee, A. Dolei, S. Amini, and B. E. Sawaya C/EBPbeta regulates human immunodeficiency virus 1 gene expression through its association with cdk9 J. Gen. Virol., February 1, 2007; 88(2): 631 - 640. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. V. Giltiay, A. A. Karakashian, A. P. Alimov, S. Ligthle, and M. N. Nikolova-Karakashian Ceramide- and ERK-dependent pathway for the activation of CCAAT/enhancer binding protein by interleukin-1{beta} in hepatocytes J. Lipid Res., November 1, 2005; 46(11): 2497 - 2505. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Schrem, J. Klempnauer, and J. Borlak Liver-Enriched Transcription Factors in Liver Function and Development. Part II: the C/EBPs and D Site-Binding Protein in Cell Cycle Control, Carcinogenesis, Circadian Gene Regulation, Liver Regeneration, Apoptosis, and Liver-Specific Gene Regulation Pharmacol. Rev., June 1, 2004; 56(2): 291 - 330. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Zhang, H. Zhang, L. Lee, and M. M. Ip The Liver-Enriched Inhibitory Protein Isoform of CCAAT/Enhancer-Binding Protein {beta}, But Not Nuclear Factor-{kappa}B, Mediates the Transcriptional Inhibition of {beta}-Casein by Tumor Necrosis Factor-{alpha} Endocrinology, June 1, 2004; 145(6): 2833 - 2844. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. N. Bradley, L. Zhou, and S. T. Smale C/EBP{beta} Regulation in Lipopolysaccharide-Stimulated Macrophages Mol. Cell. Biol., July 15, 2003; 23(14): 4841 - 4858. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. V. Reddy, K. J. Serio, C. R. Hodulik, and T. D. Bigby 5-Lipoxygenase-activating Protein Gene Expression. KEY ROLE OF CCAAT/ENHANCER-BINDING PROTEINS (C/EBP) IN CONSTITUTIVE AND TUMOR NECROSIS FACTOR (TNF) alpha -INDUCED EXPRESSION IN THP-1 CELLS J. Biol. Chem., April 11, 2003; 278(16): 13810 - 13818. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Okazaki, J. Li, H. Yu, N. Fukui, and L. J. Sandell CCAAT/Enhancer-binding Proteins beta and delta Mediate the Repression of Gene Transcription of Cartilage-derived Retinoic Acid-sensitive Protein Induced by Interleukin-1beta J. Biol. Chem., August 23, 2002; 277(35): 31526 - 31533. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Zhou, B. Gurates, S. Yang, S. Sebastian, and S. E. Bulun Malignant Breast Epithelial Cells Stimulate Aromatase Expression via Promoter II in Human Adipose Fibroblasts: An Epithelial-Stromal Interaction in Breast Tumors Mediated by CCAAT/Enhancer Binding Protein {beta} Cancer Res., March 1, 2001; 61(5): 2328 - 2334. [Abstract] [Full Text] |
||||
![]() |
V. K. Harris, C. M. Coticchia, B. L. Kagan, S. Ahmad, A. Wellstein, and A. T. Riegel Induction of the Angiogenic Modulator Fibroblast Growth Factor-binding Protein by Epidermal Growth Factor Is Mediated through Both MEK/ERK and p38 Signal Transduction Pathways J. Biol. Chem., April 6, 2000; 275(15): 10802 - 10811. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P. O'Rourke, G. C. Newbound, J. A. Hutt, and J. DeWille CCAAT/Enhancer-binding Protein delta Regulates Mammary Epithelial Cell G0 Growth Arrest and Apoptosis J. Biol. Chem., June 4, 1999; 274(23): 16582 - 16589. [Abstract] [Full Text] [PDF] |
||||
![]() |
F.-Y. J. Lee, Y. Li, E. K. Yang, S. Q. Yang, H. Z. Lin, M. A. Trush, A. J. Dannenberg, and A. M. Diehl Phenotypic abnormalities in macrophages from leptin-deficient, obese mice Am J Physiol Cell Physiol, February 1, 1999; 276(2): C386 - C394. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Baer, S. C. Williams, A. Dillner, R. C. Schwartz, and P. F. Johnson Autocrine Signals Control CCAAT/Enhancer Binding Protein beta Expression, Localization, and Activity in Macrophages Blood, December 1, 1998; 92(11): 4353 - 4365. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Diehl Roles of CCAAT/Enhancer-binding Proteins in Regulation of Liver Regenerative Growth J. Biol. Chem., November 20, 1998; 273(47): 30843 - 30846. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. Rai, F. Y. J. Lee, A. Rosen, S. Q. Yang, H. Z. Lin, A. Koteish, F. Y. Liew, C. Zaragoza, C. Lowenstein, and A. M. Diehl Impaired liver regeneration in inducible nitric oxide synthasedeficient mice PNAS, November 10, 1998; 95(23): 13829 - 13834. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Lekstrom-Himes and K. G. Xanthopoulos Biological Role of the CCAAT/Enhancer-binding Protein Family of Transcription Factors J. Biol. Chem., October 30, 1998; 273(44): 28545 - 28548. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Kim and S. M. Fischer Transcriptional Regulation of Cyclooxygenase-2 in Mouse Skin Carcinoma Cells. REGULATORY ROLE OF CCAAT/ENHANCER-BINDING PROTEINS IN THE DIFFERENTIAL EXPRESSION OF CYCLOOXYGENASE-2 IN NORMAL AND NEOPLASTIC TISSUES J. Biol. Chem., October 16, 1998; 273(42): 27686 - 27694. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Q. Yang, H. Z. Lin, M. Yin, J. H. Albrecht, and A. M. Diehl Effects of chronic ethanol consumption on cytokine regulation of liver regeneration Am J Physiol Gastrointest Liver Physiol, October 1, 1998; 275(4): G696 - G704. [Abstract] [Full Text] [PDF] |
||||